Galecto Competitors

Galecto (NASDAQ:GLTO) and Xenon Pharmaceuticals (NASDAQ:XENE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Institutional & Insider Ownership

79.9% of Xenon Pharmaceuticals shares are owned by institutional investors. 8.4% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Galecto and Xenon Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Galecto has higher earnings, but lower revenue than Xenon Pharmaceuticals.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Galecto and Xenon Pharmaceuticals, as reported by MarketBeat.

Galecto currently has a consensus price target of $14.00, suggesting a potential upside of 122.93%. Xenon Pharmaceuticals has a consensus price target of $25.25, suggesting a potential upside of 43.30%. Given Galecto's higher possible upside, research analysts clearly believe Galecto is more favorable than Xenon Pharmaceuticals.

Profitability

This table compares Galecto and Xenon Pharmaceuticals' net margins, return on equity and return on assets.

Galecto (NASDAQ:GLTO) and Kadmon (NASDAQ:KDMN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Institutional & Insider Ownership

94.8% of Kadmon shares are owned by institutional investors. 3.0% of Kadmon shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Galecto and Kadmon's top-line revenue, earnings per share (EPS) and valuation.

Galecto has higher earnings, but lower revenue than Kadmon.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Galecto and Kadmon, as reported by MarketBeat.

Galecto currently has a consensus price target of $14.00, suggesting a potential upside of 122.93%. Kadmon has a consensus price target of $12.75, suggesting a potential upside of 248.36%. Given Kadmon's higher possible upside, analysts clearly believe Kadmon is more favorable than Galecto.

Profitability

This table compares Galecto and Kadmon's net margins, return on equity and return on assets.

Summary

Kadmon beats Galecto on 5 of the 8 factors compared between the two stocks.

Galecto (NASDAQ:GLTO) and Albireo Pharma (NASDAQ:ALBO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Institutional & Insider Ownership

85.7% of Albireo Pharma shares are owned by institutional investors. 5.0% of Albireo Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Galecto and Albireo Pharma's top-line revenue, earnings per share (EPS) and valuation.

Galecto has higher earnings, but lower revenue than Albireo Pharma.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Galecto and Albireo Pharma, as reported by MarketBeat.

Galecto currently has a consensus price target of $14.00, suggesting a potential upside of 122.93%. Albireo Pharma has a consensus price target of $72.00, suggesting a potential upside of 118.98%. Given Galecto's higher possible upside, research analysts clearly believe Galecto is more favorable than Albireo Pharma.

Profitability

This table compares Galecto and Albireo Pharma's net margins, return on equity and return on assets.

Galecto (NASDAQ:GLTO) and Chinook Therapeutics (NASDAQ:KDNY) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Galecto and Chinook Therapeutics, as reported by MarketBeat.

Galecto currently has a consensus price target of $14.00, suggesting a potential upside of 122.93%. Chinook Therapeutics has a consensus price target of $30.3333, suggesting a potential upside of 104.68%. Given Galecto's higher possible upside, research analysts clearly believe Galecto is more favorable than Chinook Therapeutics.

Profitability

This table compares Galecto and Chinook Therapeutics' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Galecto and Chinook Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Galecto has higher earnings, but lower revenue than Chinook Therapeutics.

Summary

Galecto beats Chinook Therapeutics on 4 of the 6 factors compared between the two stocks.

Magenta Therapeutics (NASDAQ:MGTA) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

Institutional & Insider Ownership

59.3% of Magenta Therapeutics shares are owned by institutional investors. 10.9% of Magenta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Magenta Therapeutics and Galecto, as provided by MarketBeat.com.

Magenta Therapeutics currently has a consensus target price of $17.6667, suggesting a potential upside of 43.40%. Galecto has a consensus target price of $14.00, suggesting a potential upside of 122.93%. Given Galecto's higher possible upside, analysts plainly believe Galecto is more favorable than Magenta Therapeutics.

Profitability

This table compares Magenta Therapeutics and Galecto's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Magenta Therapeutics and Galecto's gross revenue, earnings per share and valuation.

Evolus (NASDAQ:EOLS) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

Institutional & Insider Ownership

21.7% of Evolus shares are owned by institutional investors. 10.1% of Evolus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Evolus and Galecto, as provided by MarketBeat.com.

Evolus currently has a consensus target price of $13.8889, suggesting a potential upside of 2.27%. Galecto has a consensus target price of $14.00, suggesting a potential upside of 122.93%. Given Galecto's stronger consensus rating and higher possible upside, analysts plainly believe Galecto is more favorable than Evolus.

Profitability

This table compares Evolus and Galecto's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Evolus and Galecto's gross revenue, earnings per share and valuation.

Galecto has lower revenue, but higher earnings than Evolus.

Summary

Galecto beats Evolus on 5 of the 9 factors compared between the two stocks.